UNSPSC 51171528: Betaine anhydrous

This classification denotes a nutritional supplement with the molecular formula C5H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3SCV180C9W, chemically known as 2-(trimethylammonio)ethanoic acid, hydroxide, inner salt but more generally known as betaine, which bears US NIH Compound Identifier 247.

Betaine comes in many forms, including base, aldehyde, aldehyde chloride, aldehyde hydrate, alpha-d-glucofuranuronate, amide, aspartate, cephaloridine, chloride, choline citrate, citrate, d-galacturonate, d-gluconate, hydrate, hydrazide hydrochloride, hydrochloride, l-ascorbate, lauryldimethylaminoacetate, methyl ester, monohydrate, nicotinate, solution, and tartrate. European Medicines Agency schedules Betaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13055MIG.

UNSPSC 51171528 Betaine anhydrous (Commodity) encompasses chemical additives and pharmaceutical precursor materials that state and local health and human services agencies, correctional departments, and multistate cooperative purchasing alliances acquire for clinical testing, pharmaceutical manufacturing, and healthcare delivery operations. Recent solicitations show that state and local bodies are purchasing betaine anhydrous principally as a component within broader pharmaceutical supply chains, drug-testing specimen processing systems, and generic medication programs rather than as a standalone bulk chemical commodity. The issuing bodies span state health and human services commissions, county corrections and community supervision departments, and multistate cooperative purchasing vehicles serving multiple state and local jurisdictions simultaneously.

Recent activity centers on Texas and the upper Midwest. The Collin County Community Supervision and Corrections Department (Texas) issued RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services with a July 23, 2026 response deadline and an estimated contract value of $600,000 over two years plus optional renewals; the scope includes immunoassay screening and confirmation testing methodologies that may incorporate betaine anhydrous or related buffering agents within specimen processing chemistry. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs without specifying betaine anhydrous explicitly. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, covering distributed supply across state and local facilities in Minnesota, Oregon, and other participating jurisdictions. No recent solicitations name betaine anhydrous as a primary line item or specify its application in detail, suggesting the code may see limited standalone procurement activity at the state and local level.